Merck & Company Inc (MRK)vsOmeros Corporation (OMER)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
OMER
Omeros Corporation
$18.28
-1.67%
HEALTHCARE · Cap: $1.37B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 173158% more annual revenue ($66.57B vs $38.42M). OMER leads profitability with a 324.9% profit margin vs 4.8%. OMER appears more attractively valued with a PEG of 0.81. OMER earns a higher WallStSmart Score of 44/100 (D).
MRK
Hold36
out of 100
Grade: F
OMER
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
+88.2%
Fair Value
$95.52
Current Price
$18.28
$77.24 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Attractively priced relative to earnings
Keeps 325 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 0.3%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : OMER
The strongest argument for OMER centers on P/E Ratio, Profit Margin, Debt/Equity. Profitability is solid with margins at 324.9% and operating margin at 0.3%. Revenue growth of 14.9% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : OMER
The primary concerns for OMER are EPS Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while OMER is a mature play — different risk/reward profiles.
OMER carries more volatility with a beta of 2.54 — expect wider price swings.
OMER is growing revenue faster at 14.9% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
OMER scores higher overall (44/100 vs 36/100), backed by strong 324.9% margins and 14.9% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Omeros Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?